[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Ryu SH, Han SY, Suh SH, Koo YH, Cho JH, Han SH, Lee SW, Cho JH, Jeong JS: [A case of primary small cell carcinoma of the liver]. Korean J Hepatol; 2005 Sep;11(3):289-92
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary small cell carcinoma of the liver].
  • Primary small cell carcinoma of the liver is an extremely rare tumor.
  • Extrapulmonary small cell carcinoma shares many features of pulmonary small cell carcinoma, including the histological appearance, the aggressive clinical behavior and the frequent short-lasting response to either chemotherapy or radiotherapy.
  • We experienced a 56-year-old man with small cell carcinoma that arose in the liver.
  • The pathological findings showed nests of small round cells with fine granular chromatin, inconspicuous nucleoli and scanty cytoplasm.
  • The tumor did not decrease in size despite chemotherapy.
  • We report this case along with a review of the relevant literatures.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Liver Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177556.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


2. Park JS, Kim L, Kim CH, Bang BW, Lee DH, Jeong S, Shin YW, Kim HG: Synchronous large-cell neuroendocrine carcinoma and adenocarcinoma of the colon. Gut Liver; 2010 Mar;4(1):122-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous large-cell neuroendocrine carcinoma and adenocarcinoma of the colon.
  • Large-cell neuroendocrine carcinoma of the colon is a rare entity with a prognosis that is usually poor due to the high likelihood of early metastasis.
  • Microscopic examination of the tumor showed that the location was the proximal transverse colon, with small nests containing rosettes and palisading patterns of large tumor cells with faintly granular cytoplasm.
  • The tumors were diagnosed as a large-cell neuroendocrine carcinoma of the colon.
  • In addition, the tumor of the cecum showed microscopic findings consistent with a well-differentiated adenocarcinoma.
  • Postoperative chemotherapy was applied.
  • This is the first case of a synchronous large-cell neuroendocrine carcinoma and adenocarcinoma of the colon.
  • The patient was treated successfully with debulking surgery and systemic chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Esp Enferm Dig. 2008 Jan;100(1):11-6 [18358055.001]
  • [Cites] Int J Colorectal Dis. 2008 Mar;23(3):325-7 [18064472.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):553-76 [16183527.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):491-505 [16183523.001]
  • [Cites] Pathol Int. 2005 Aug;55(8):524-9 [15998383.001]
  • [Cites] Gynecol Oncol. 2001 Jul;82(1):187-91 [11426984.001]
  • [Cites] Surgery. 1994 Jun;115(6):762-6 [8197570.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1049-51 [15154621.001]
  • [Cites] Virchows Arch. 2002 Sep;441(3):256-63 [12242522.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3500-5 [8012973.001]
  • (PMID = 20479925.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871610
  • [Keywords] NOTNLM ; Chemotherapy / Colonic neoplasms / Multiple primary neoplasms / Neuroendocrine carcinoma
  •  go-up   go-down


3. Deshpande AH, Kotwal MN, Bobhate SK: Glassy cell carcinoma of the uterine cervix a rare histology. Report of three cases with a review of the literature. Indian J Cancer; 2004 Apr-Jun;41(2):92-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glassy cell carcinoma of the uterine cervix a rare histology. Report of three cases with a review of the literature.
  • Glassy cell carcinoma is a poorly differentiated variant of adenosquamous carcinoma of the cervix associated with an aggressive course and a poor prognosis.
  • We present three cases of glassy cell carcinoma of the cervix.
  • Patients presented with a cervical growth which was biopsied.
  • Histology the tumours showed nests of cells with a granular or clear cytoplasm, displaying marked pleomorphism and mitoses.
  • Two tumours showed a pure glassy cell pattern and one showed glandular differentiation with intracellular and extracellular mucin.
  • Patients were treated with a combination of surgery, radiotherapy and chemotherapy but showed a poor response.
  • Two patients died of the disease of pelvic or distant metastases within two years of diagnosis and one was lost to follow up.
  • Although glassy cell carcinoma runs an aggressive clinical course, an early diagnosis may help in a more effective management and offer a better prognosis.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15318016.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 10
  •  go-up   go-down


Advertisement
4. Gütgemann I, Lehman NL, Jackson PK, Longacre TA: Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod Pathol; 2008 Apr;21(4):445-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma.
  • Clear cell carcinoma is a clinically and pathologically distinct entity among surface epithelial ovarian neoplasms, recognized for its resistance to standard platinum-based chemotherapy at advanced stage disease and poor prognosis.
  • Despite advances in our understanding of the biology of other surface epithelial ovarian neoplasms, very little is known about the molecular genetic mechanisms that are involved in clear cell tumorigenesis.
  • Early mitotic inhibitor-1 (Emi1) protein is a key cell cycle regulator, that promotes S-phase and mitotic entry by inhibiting the anaphase promoting complex.
  • In cell culture systems, overexpression of Emi1 leads to tetraploidy and genomic instability, especially in the absence of normal p53 function.
  • We investigated Emi1 protein expression in ovarian neoplasms using a tissue microarray constructed from 339 primary ovarian surface epithelial (serous, endometrioid, clear cell, and mucinous) and peritoneal (serous) neoplasms, stromal and mesenchymal tumors, germ cell tumors, and normal ovarian tissue.
  • Significant overexpression of Emi1 protein was present in 82% (27/33) clear cell carcinoma, including one borderline tumor in a diffuse, granular cytoplasmic and perinuclear staining pattern, independent of patient age, presence of ovarian and/or pelvic endometriosis, and FIGO stage.
  • In contrast, only 10% (17/177) primary ovarian and primary peritoneal serous carcinomas, 0% (0/10) mucinous carcinomas, and 19% (6/32) endometrioid carcinomas exhibited significant Emi1 protein overexpression.
  • Accumulation of Emi1 protein was not linked to Ki-67 labeling index, but was directly correlated with cyclin E and inversely correlated with ER in clear cell carcinoma (P<0.001).
  • Emi1 protein expression was present in mixed endometrioid/clear cell tumors but absent in tumors with mixed serous/clear cell histology.
  • These findings represent a potentially important insight into the molecular pathway underlying ovarian carcinogenesis and provide a possible cell cycle model for the development and progression of ovarian clear cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Cell Cycle Proteins / biosynthesis. F-Box Proteins / biosynthesis. Ovarian Neoplasms / metabolism. Signal Transduction / physiology. Ubiquitin-Protein Ligase Complexes / metabolism
  • [MeSH-minor] Anaphase-Promoting Complex-Cyclosome. Cyclin E / metabolism. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Receptors, Estrogen / metabolism. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18204430.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin E; 0 / F-Box Proteins; 0 / FBXO5 protein, human; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; EC 6.3.2.19 / Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Ubiquitin-Protein Ligase Complexes
  •  go-up   go-down


5. Ideo A, Hashimoto K, Shimada J, Kawase M, Sakagami H: Type of cell death induced by alpha-trifluoromethyl acyloins in oral squamous cell carcinoma. Anticancer Res; 2009 Jan;29(1):175-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type of cell death induced by alpha-trifluoromethyl acyloins in oral squamous cell carcinoma.
  • We previously reported that alpha-trifluoromethyl acyloins (TFs) induced various types of cell death, depending on the target cancer cell line.
  • We investigated here what type of cell death is induced by a-trifluoromethyl acyloins in two human oral squamous cell carcinoma cell lines (HSC-2, HSC-4).
  • When HSC-2 and HSC-4 cells that had been transfected with expression vector encording the microtubule-associated protein 1 light chain 3 (LC3) gene fused to green fluorescent protein (GFP) were treated with TFs, LC3-GFP fusion protein was accumulated as granular dots in autophagosomes.
  • These data suggest that alpha-trifluoromethyl acyloins may induce autophagic cell death in HSC-2 and HSC-4 cells following the early stage of necrosis or apoptosis, respectively.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Fatty Alcohols / pharmacology. Hydrocarbons, Fluorinated / pharmacology. Mouth Neoplasms / drug therapy. Mouth Neoplasms / pathology
  • [MeSH-minor] Caspases / metabolism. Cell Death / drug effects. Cell Death / physiology. Cell Line, Tumor. Enzyme Activation / drug effects. Humans


6. Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L: Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res; 2002 Mar;8(3):788-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Osteosarcoma (OS) and skeletal Ewing's sarcoma (EWS), the most common pediatric primary bone tumors, are aggressive malignancies with a tendency for early pulmonary metastasis.
  • Advances in therapy have increased the overall 5-year survival to approximately 70%; however, patients who relapse often fail to respond to salvage therapy.
  • Thus, more effective adjuvant chemotherapy is needed for these patients.
  • Several reports have claimed expression of the HER2/neu (c-erbB-2) gene in a high percentage of OSs and that its expression is a poor prognostic factor and have advocated monoclonal antibody therapy in those cases.
  • Thirty-four cases (44%) demonstrated granular cytoplasmic staining, but none showed the distinct membranous staining characteristic of expression exhibited by breast carcinomas.
  • To validate these immunohistochemical results, reverse transcription-PCR using RNA derived from archival material (n = 48) and several different primer pairs also failed to demonstrate the presence of amplifiable HER2/neu mRNA, although a known HER2/neu-positive breast carcinoma showed amplifiable mRNA.
  • Our results show that HER2/neu is not expressed by these sarcomas, and we conclude that HER2/neu is therefore not an important prognostic factor and that anti-HER2/neu monoclonal antibody therapy is not appropriate for these patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Differentiation. Child. DNA Primers / chemistry. Female. Gene Expression. Humans. Immunoenzyme Techniques. Lung Neoplasms / secondary. Male. Middle Aged. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction


7. Chiang MJ, Fang TJ, Li HY, Chen IH, Lee KF: Malignant granular cell tumor in larynx mimicking laryngeal carcinoma. Am J Otolaryngol; 2004 Jul-Aug;25(4):270-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant granular cell tumor in larynx mimicking laryngeal carcinoma.
  • Pathologic findings showed malignant granular cell tumor.
  • Postoperative palliative chemotherapy was done for his lung metastasis.
  • [MeSH-major] Granular Cell Tumor / diagnosis. Laryngeal Neoplasms / diagnosis. Lung Neoplasms / secondary
  • [MeSH-minor] Aged. Carcinoma / diagnosis. Chemotherapy, Adjuvant. Deglutition Disorders / etiology. Diagnosis, Differential. Dyspnea / etiology. Humans. Immunohistochemistry. Laryngoscopy. Male. Palliative Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15239036.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Lemos LB, Qu Z, Garg K, Papasozomenos S: Pseudoneoplastic proliferation of histiocytes with paclitaxel-induced ultrastructural changes in a mastectomy specimen. Ann Diagn Pathol; 2004 Oct;8(5):299-304
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 49-year-old Hispanic woman with a T4N1M0 infiltrating duct carcinoma of the left breast underwent four courses of FAC (doxorubicin 86 mg, 5-fluorouracil 860 mg, cyclophosphamide 86 mg, and dexamethasone 10 mg) adjuvant chemotherapy plus four courses of paclitaxel (Taxol; Bristol-Myers Squibb Oncology, Princeton, NJ) and subsequent mastectomy.
  • The tumor shrunk from 6.5 cm to 2.5 cm after the treatment.
  • The tumor showed typical chemotherapy changes and a massive proliferation of histiocytes that mimicked a neoplasm.
  • These findings ruled out histiocytoid carcinoma, granular cell tumor, and Erdheim-Chester disease.
  • The treated breast carcinoma cells were tubulin-positive but the proliferating histiocytes were tubulin-negative.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Histiocytes / ultrastructure. Mastectomy. Paclitaxel / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor. Cell Proliferation / drug effects. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Intermediate Filaments / drug effects. Intermediate Filaments / ultrastructure. Lymph Nodes / pathology. Lymphatic Metastasis. Mastectomy, Modified Radical. Middle Aged. Sentinel Lymph Node Biopsy. Tubulin / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15494938.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / Tubulin; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil; CAF protocol
  •  go-up   go-down


9. Hao LS, Zhu X, Zhao LH, Qian K, Zhou Y, Bu J, Wu XT: Clear cell adenocarcinoma of colorectum: a case report and review of the literature. Acta Gastroenterol Belg; 2007 Apr-Jun;70(2):235-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of colorectum: a case report and review of the literature.
  • Primary clear cell adenocarcinoma of the colorectum is a rare neoplasm, which differs from ordinary carcinomas of the colorectum in morphological features, but shares some traits of clear cell carcinoma of other organs.
  • The tumor is usually composed of polygonal or oval cells with abundant granular and clear cytoplasm.
  • We report the first case of clear cell adenocarcinoma of the colorectum in China and review the related published cases.
  • By immunoperoxidase and histochemical staining, we clarified the clinicopathological characteristics, diagnosis and differential diagnoses, and pursued its potential pathogenesis.
  • Nevertheless, the patient has survived for one year with the help of operation and postoperative adjuvant chemotherapy.
  • Regardless of the stage and differentiation, surgical therapy and proper adjuvant chemotherapy are effective means to treat the clear cell adenocarcinoma of the colorectum.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Colectomy / methods. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Colonoscopy. Diagnosis, Differential. Follow-Up Studies. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17715642.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


10. Cao Y, Karsten U, Zerban H, Bannasch P: Expression of MUC1, Thomsen-Friedenreich-related antigens, and cytokeratin 19 in human renal cell carcinomas and tubular clear cell lesions. Virchows Arch; 2000 Feb;436(2):119-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MUC1, Thomsen-Friedenreich-related antigens, and cytokeratin 19 in human renal cell carcinomas and tubular clear cell lesions.
  • The expression of MUC1, MUC2, mucin-associated Thomsen-Friedenreich-related antigens (TF, sialosyl-TF, Tn, and sialosyl-Tn), and cytokeratin 19 (CK19) was systematically investigated in situ in 58 resected human kidney tumours, surrounding tissue of normal appearance, and two normal kidneys obtained at autopsy, using monoclonal antibodies.
  • In kidney tissues of normal appearance, TF, s-TF, MUC1 and CK19 were positive in distal tubules and collecting ducts but negative in proximal tubules.
  • Almost all renal cell carcinomas (RCCs) showed strong immunoreactivity for MUC1, but all were negative for MUC2.
  • In addition, the immunomorphological characteristics of the majority of clear-cell RCCs and clear/granular RCCs with anti-MUC1 and anti-CK 19 closely resembled those of the collecting duct and the distal tubule rather than the proximal tubule.
  • In the renal tissue of otherwise normal appearance adjacent to clear-cell RCCs and clear/granular RCCs, clear cells with excessive storage of glycogen were often found in the collecting duct system, but only rarely in the proximal tubules.
  • These results suggest that the majority of clear-cell RCCs and clear/granular RCCs may originate from the collecting duct system.
  • [MeSH-major] Adenoma, Oxyphilic / metabolism. Antigens, Tumor-Associated, Carbohydrate / metabolism. Carcinoma, Renal Cell / metabolism. Keratins / metabolism. Kidney Neoplasms / metabolism. Kidney Tubules, Collecting / metabolism. Kidney Tubules, Distal / metabolism. Mucin-1 / metabolism. Peptide Fragments / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10755601.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / MUC1 tandem repeat peptide; 0 / Mucin-1; 0 / Peptide Fragments; 3554-90-3 / Thomsen-Friedenreich antigen; 68238-35-7 / Keratins
  •  go-up   go-down


11. Lauro S, Trasatti L, Bria E, Gelibter A, Larosa G, Vecchione A: Malignant bronchial Abrikossoff's tumor and small cell lung cancer: a case report and review. Anticancer Res; 2001 Jan-Feb;21(1B):563-5
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant bronchial Abrikossoff's tumor and small cell lung cancer: a case report and review.
  • Bronchoscopy showed an endobronchial mass; washing cytology was negative and histology findings suggested diagnosis of granular cell tumor (GCT), also called Abrikossoff's tumor.
  • After 3 weeks a new washing cytology test revealed the presence of small cell lung cancer (SCLC).
  • The patient was referred to our institution and started chemotherapy with cisplatin and etoposide.
  • After 6 cycles of treatment, the CT scan showed complete, disappearance of the neoplasm and bronchoscopy examination showed no endobronchial lesion, defining the mucosal surface as normal.
  • We have reviewed and summarized the international literature with regard to bronchial localization of malignant granular cell tumor and its association with SCLC, therefore concluding that our case is the first malignant endobronchial GCT linked to SCLC.
  • [MeSH-major] Bronchial Neoplasms / pathology. Carcinoma, Small Cell / pathology. Granular Cell Tumor / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bronchoalveolar Lavage Fluid / cytology. Bronchoscopy. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Humans. Male. Middle Aged. Remission Induction. Smoking / adverse effects. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11299804.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Beeram M, Rowinsky EK, Weiss GR, Syed S, Mita A, Patnaik A, Mita M, Goldston M, De Bono JS, Tolcher AW: Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging. J Clin Oncol; 2004 Jul 15;22(14_suppl):3050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging.
  • Tumor histology was: clear cell (77 %) and granular (13 %).
  • Median number of prior therapies was 2 (range 0-4): nephrectomy (90%), immunotherapy (83%), radiation (37%) and chemotherapy (20%).
  • Prolonged stable disease (SD) lasting more than 6 months was noted in 7 pts (23 %) including 3 patients who remained on treatment for 14, 14, and 15 months.
  • CONCLUSION: OSI-774 induces prolonged stable disease (≥ 6 months) and antitumor response in a significant subset of patients with metastatic renal cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015214.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Kim YH, Kwon R, Jung GJ, Roh MH, Han SY, Kwon HC, Jeong JS, Shin TB, Oh JY, Lee KN: Extrapulmonary small-cell carcinoma of the liver. J Hepatobiliary Pancreat Surg; 2004;11(5):333-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrapulmonary small-cell carcinoma of the liver.
  • On subsequent biopsy of the mass, the lesion was histologically diagnosed as malignant small round-cell tumor, consistent with metastatic small-cell carcinoma.
  • On pathological examination, the mass showed a yellowish-gray granular appearance with multifocal hemorrhage and necrosis.
  • The phenotypes shown by immunohistochemistry revealed characteristic patterns of small-cell carcinoma (neuron-specific enolase [NSE]+, synaptophysin+, c-Kit+, cluster designation [CD]56+, epithelial membrane antigen [EMA]+, cytokeratin [CK]7-).
  • High resolution-computed tomography (HRCT) revealed inactive pulmonary tuberculosis with small calcified tuberculoma in the right upper lobe.
  • The postoperative course was uneventful, and platinum-based chemotherapy (cisplatin, etoposide) was initiated.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Comorbidity. Humans. Immunohistochemistry. Male. Middle Aged. Tomography, X-Ray Computed. Tuberculoma / epidemiology. Tuberculoma / radiography. Tuberculosis, Pulmonary / epidemiology. Tuberculosis, Pulmonary / radiography

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15549433.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Katayama T, Watari M: [An advanced aged case of intrapulmonary metastasis of non-small cell lung cancer successfully controlled with S-1 capsule therapy alone for an extended period]. Gan To Kagaku Ryoho; 2007 May;34(5):753-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An advanced aged case of intrapulmonary metastasis of non-small cell lung cancer successfully controlled with S-1 capsule therapy alone for an extended period].
  • About 7 months after surgery for a non-small cell lung cancer StageIII B, granular shadows were noted on his bilateral lungs on CT; and the level of CA 19-9 , a tumor marker, had increased.
  • These findings led to a diagnosis of intrapulmonary tumor metastasis.
  • Treatment with a platinum-based antineoplastic agent was recommended,but the patient refused it because of his age.
  • Because the tumor appeared to increase in size, treatment was initiated using S-1 capsules (hereafter abbreviated to S-1) alone.
  • Each course consisted of S-1 at a dosage of 100 mg/body/day, twice daily for 21 days, followed by 14 days of drug withdrawal.
  • It has been about 18 months after the S-1 single therapy was started.
  • This therapy is still being continued.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Oxonic Acid / administration & dosage. Tegafur / administration & dosage
  • [MeSH-minor] Aged, 80 and over. Drug Administration Schedule. Drug Combinations. Humans. Male. Quality of Life. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496451.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


15. Callan MB, Preziosi D, Mauldin E: Multiple papillomavirus-associated epidermal hamartomas and squamous cell carcinomas in situ in a dog following chronic treatment with prednisone and cyclosporine. Vet Dermatol; 2005 Oct;16(5):338-45
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple papillomavirus-associated epidermal hamartomas and squamous cell carcinomas in situ in a dog following chronic treatment with prednisone and cyclosporine.
  • A 4-year-old, spayed female toy fox terrier developed multiple epidermal hamartomas and squamous cell carcinomas in situ following chronic immunosuppressive therapy with prednisone and cyclosporine for management of an immune-mediated nonregenerative anaemia.
  • Immunohistochemical staining was positive for papillomavirus antigen within both benign (n = 19) and malignant (n = 8) cutaneous lesions that developed during a 3-year period of observation, with positive staining most often seen in keratinocytes in the granular cell layer.
  • Treatment of the papillomavirus infection with interferon-alpha was discontinued after 2 weeks because of diarrhoea and a further increase in liver enzymes.
  • The cutaneous lesions of this dog persisted and new lesions developed during the year following discontinuation of both cyclosporine and prednisone.
  • This is the first reported case of papillomavirus-associated squamous cell carcinoma in situ developing in a dog following chronic administration of cyclosporine and prednisone.
  • [MeSH-major] Carcinoma, Squamous Cell / veterinary. Cyclosporine / adverse effects. Dog Diseases / diagnosis. Prednisone / adverse effects. Skin Neoplasms / veterinary
  • [MeSH-minor] Anemia / drug therapy. Anemia / veterinary. Animals. Diagnosis, Differential. Dogs. Drug Administration Schedule. Drug Therapy, Combination. Female. Hamartoma / diagnosis. Hamartoma / veterinary. Immunocompromised Host. Papillomavirus Infections / diagnosis. Papillomavirus Infections / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16238815.001).
  • [ISSN] 0959-4493
  • [Journal-full-title] Veterinary dermatology
  • [ISO-abbreviation] Vet. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 83HN0GTJ6D / Cyclosporine; VB0R961HZT / Prednisone
  •  go-up   go-down


16. Gollob JA, Veenstra KG, Mier JW, Atkins MB: Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. J Immunother; 2001 Jan-Feb;24(1):91-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12.
  • In this article, the authors describe two patients with renal cell cancer in whom grade 4 neutropenia and grade 3 hemolytic anemia developed, respectively, during treatment with twice-weekly intravenous recombinant human interleukin-12 (rhIL-12) during a phase 1 trial.
  • The severe neutropenia was associated with bone marrow agranulocytosis and a preponderance of large granular lymphocytes in the peripheral blood, whereas the hemolytic anemia was negative for the Coombs test and associated with splenomegaly.
  • The agranulocytosis and hemolytic anemia persisted after the rhIL-12 was stopped, but both subsequently responded to treatment with cyclophosphamide. steroids, or both.
  • These findings indicate that rhIL-12 can induce unique hematologic toxic effects that can be reversed with immunosuppressive drugs.
  • [MeSH-major] Anemia, Hemolytic / immunology. Carcinoma, Renal Cell / drug therapy. Interleukin-12 / adverse effects. Interleukin-12 / therapeutic use. Kidney Neoplasms / drug therapy. Neutropenia / immunology
  • [MeSH-minor] Aged. Female. Humans. Injections, Intravenous. Male. Middle Aged. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Recombinant Proteins / therapeutic use

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11211153.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 187348-17-0 / Interleukin-12
  •  go-up   go-down


17. Uchida N, Tsuzuki Y, Ando T, Mochida Y, Yoshikawa M, Sekihara M, Kobayashi M, Ide M, Ohno Y, Kuwano H: Malignant proliferating trichilemmal tumor in the skin over the breast: a case report. Breast Cancer; 2000 Jan;7(1):79-82
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is composed of multiple cysts consisting of squamous epithelium with trichilemmal keratinization without granular layer interposition.
  • We describe a 67-year-old woman with a malignant proliferating trichilemmal tumor in the skin over the breast.
  • We first misdiagnosed the disease as a primary squamous cell carcinoma of the breast with a metastatic lymph node in the axilla because of the disease site and our unfamiliarity with the disease.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Carcinoma, Squamous Cell / diagnosis. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Diagnostic Errors. Doxorubicin / administration & dosage. Fadrozole / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Mastectomy, Radical. Mitomycin / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hair Problems.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11029776.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; H3988M64PU / Fadrozole; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Ye L, Wu XL, Xu L, Huang Q, Sun L, He Y, Yang KX: [Ovarian steroid cell tumor, not otherwise specified: a clinicopathologic study]. Zhonghua Bing Li Xue Za Zhi; 2007 Aug;36(8):516-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian steroid cell tumor, not otherwise specified: a clinicopathologic study].
  • OBJECTIVE: To study the clinicopathologic features, diagnostic criteria, differential diagnosis and treatment options of ovarian steroid cell tumor, not otherwise specified (NOS).
  • METHODS: Light microscopy and immunohistochemical study was carried out in 8 cases of ovarian steroid cell tumor, NOS.
  • RESULTS: The 7 cases of benign ovarian steroid cell tumor, NOS were composed mainly of polygonal cells with granular eosinophilic cytoplasm and larger cells with vacuolated cytoplasm.
  • They resembled the architecture of normal adrenal gland, with formation of cell nests and trabeculae.
  • The single case of malignant ovarian steroid cell tumor had evidence of significant cellular pleomorphism, haemorrhage and coagulative tumor necrosis.
  • Differential diagnosis included oxyphilic granulosa cell tumor, thecoma, Sertoli cell tumor and clear cell carcinoma.
  • The treatment options of benign ovarian steroid cell tumor, NOS was local excision or ipsilateral salpingo-oophorectomy, while the malignant counterpart should be treated with a combination of surgery and chemotherapy, including administration of GnRH agonist.
  • CONCLUSIONS: Ovarian steroid cell tumor, NOS, is the most common type of ovarian steroid cell tumors.
  • Most of which are associated with a benign clinical outcome.
  • Immunohistochemistry is an important adjunct for diagnosis.
  • The treatment options of ovarian steroid cell tumor, NOS depend on its malignant potential.
  • [MeSH-minor] Adolescent. Adult. Calbindin 2. Diagnosis, Differential. Female. Granulosa Cell Tumor / pathology. Humans. Ovariectomy / methods. Sertoli Cell Tumor / pathology. Thecoma / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980097.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins
  • [Number-of-references] 27
  •  go-up   go-down


19. Bacchi CE, Silva TR, Zambrano E, Plaza J, Suster S, Luzar B, Lamovec J, Pizzolitto S, Falconieri G: Epithelioid angiosarcoma of the skin: a study of 18 cases with emphasis on its clinicopathologic spectrum and unusual morphologic features. Am J Surg Pathol; 2010 Sep;34(9):1334-43
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid angiosarcoma of the skin: a study of 18 cases with emphasis on its clinicopathologic spectrum and unusual morphologic features.
  • Diverging phenotypes included syncytial growth of large cells with clear nuclei and prominent nucleoli, micronodules of tumor cells scattered in dermis, predominance of discohesive plasmacytoid polygonal cells with abundant bright eosinophilic cytoplasm, sheets of clear cells with coarse granular cytoplasm, trabecular and cord arrangement of tumor cells splaying the dermal collagen, or a pseudoglandular appearance owing to clear cell tubular arrangement with open lumina.
  • These cases posed further diagnostic challenges simulating lymphoma, melanoma, lymphoepithelioma-like carcinoma, adnexal carcinoma, and neuroendocrine carcinoma.
  • Therapeutic modalities included combined local excision, chemotherapy, and radiotherapy, depending on patient clinical status.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697249.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res; 2005 May 15;11(10):3714-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
  • PURPOSE: Renal cancer response to interleukin 2 (IL-2) therapy and patient survival has been correlated with tumor histology and carbonic anhydrase IX (CAIX) expression.
  • In an effort to confirm and expand these observations, we examined CAIX expression in pathology specimens from renal cancer patients who had previously received IL-2 therapy.
  • EXPERIMENTAL DESIGN: Paraffin-embedded tissue sections of renal cancer were immunostained with the MN-75 monoclonal antibody to CAIX and expression levels were correlated with histologic findings and clinical outcome.
  • RESULTS: Tissue specimens were obtained from 66 patients; 27 of whom (41%) had responded to IL-2-based therapy.
  • Fifty-eight specimens were assessed as clear cell, with 56, 33, and 4 having alveolar, granular, and papillary features, respectively.
  • CONCLUSIONS: CAIX expression seems to be an important predictor of outcome in renal cell carcinoma patients receiving IL-2-based therapy and may enhance prognostic information obtained from pathology specimens.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Antineoplastic Agents / therapeutic use. Carbonic Anhydrases / biosynthesis. Gene Expression Profiling. Interleukin-2 / therapeutic use. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Male. Odds Ratio. Predictive Value of Tests. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2005 May 15;11(10):3601-3 [15897553.001]
  • [CommentIn] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8886; author reply 8886 [16361579.001]
  • (PMID = 15897568.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50-CA 10194
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Interleukin-2; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


21. Alvarez MG, Milanesio M, Rivarola V, Durantini E, Batlle A, Fukuda H: Endogenous and exogenous porphyrins as photosensitizers in the Hep-2 human carcinoma cell line. Cell Mol Biol (Noisy-le-grand); 2009;55(2):8-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endogenous and exogenous porphyrins as photosensitizers in the Hep-2 human carcinoma cell line.
  • The photodynamic activity of three photosensitizers (PS): AL-induced PPIX, the porphyrin derivative 5-(4-trimethylammoniumphenyl)-10, 5, 20-tris (2,4,6- trimethoxyphenyl) porphyrin (CP) and the molecular dyad porphyrin-C(60) (P-C(60)), the last two incorporated into liposomal vesicles, was evaluated on Hep-2 human larynx carcinoma cell line.
  • ALA-induced accumulation of the endogenous PS PPIX, reached saturation values between 5 and 24 h incubation time; the maximal PPIX content was 5.7 nmol/106 cells.
  • Under violet-blue exciting light, the fluorescence of PPIX and P-C(60) was found in the cytoplasm showing a granular appearance indicating lysosomal localization.
  • Cell morphology was analyzed using Hoechst-33258, toluidine blue staining, TUNEL assay and DNA fragmentation, 24 h after irradiation with 54 J/cm2.
  • When photosensitized with ALA and P-C(60), chromatine condensation characteristic of apoptotic cell death was found; instead, 58 % of necrotic cells were observed with CP.
  • The results show that in the Hep-2 cells, of the three PS analyzed, the molecular dyad P-C(60) was more efficient than CP and PPIX, and confirm that PDT can induce different mechanisms of cell death depending on the PS and the irradiation dose.
  • [MeSH-minor] Aminolevulinic Acid / chemistry. Carcinoma / drug therapy. Cell Line, Tumor. Cell Survival / drug effects. Fullerenes / chemistry. Humans. Laryngeal Neoplasms / drug therapy. Light. Liposomes / chemistry. Liposomes / metabolism. Microscopy, Fluorescence. Photochemotherapy. Protoporphyrins / chemistry

  • Hazardous Substances Data Bank. FULLERENES .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19656445.001).
  • [ISSN] 1165-158X
  • [Journal-full-title] Cellular and molecular biology (Noisy-le-Grand, France)
  • [ISO-abbreviation] Cell. Mol. Biol. (Noisy-le-grand)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Fullerenes; 0 / Liposomes; 0 / Photosensitizing Agents; 0 / Porphyrins; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid; NP9U26B839 / fullerene C60
  •  go-up   go-down


22. Haiman M, Salvenmoser W, Scheiber K, Lingenhel A, Rudolph C, Schmitz G, Kronenberg F, Dieplinger H: Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue. Kidney Int; 2005 Sep;68(3):1130-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue.
  • METHODS: To investigate whether the human kidney directly metabolizes ApoA-IV and which kidney tissue compartment is involved therein, ApoA-IV was localized by immunohistochemistry in 28 healthy kidney tissue samples obtained from patients undergoing nephrectomy.
  • ApoA-IV mRNA expression was analyzed by real-time polymerase chain reaction (PCR) to exclude de novo synthesis in the kidney.
  • RESULTS: ApoA-IV immunostaining was detected in proximal and distal tubular cells, capillaries and blood vessels but not inside glomeruli.
  • ApoA-IV was predominantly found in the brush border of proximal tubules and in intracellular granules and various plasma membrane domains of both proximal and distal tubules. mRNA expression analysis revealed that no ApoA-IV was produced in the kidney.
  • The granular staining pattern probably represents lysosomes degrading ApoA-IV.
  • The additional ApoA-IV localization in distal tubules suggests a rescue function to reabsorb otherwise escaping ApoA-IV in case proximal tubules cannot reabsorb all ApoA-IV.
  • Since no mRNA expression could be detected in any kidney cells, the observed ApoA-IV immunoreactivity represents uptake and not de novo synthesis of ApoA-IV.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibody Specificity. Capillaries / metabolism. Carcinoma, Hepatocellular. Cell Line, Tumor. Female. Gene Expression. Glomerular Mesangium / blood supply. Glomerular Mesangium / cytology. Glomerular Mesangium / metabolism. Humans. Immunohistochemistry. Kidney Tubules, Distal / blood supply. Kidney Tubules, Distal / cytology. Kidney Tubules, Distal / metabolism. Kidney Tubules, Proximal / blood supply. Kidney Tubules, Proximal / cytology. Kidney Tubules, Proximal / metabolism. Liver Neoplasms. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16105043.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins A; 0 / apolipoprotein A-IV
  •  go-up   go-down






Advertisement